Epithelial Ovarian Cancer Market Report 2026

Epithelial Ovarian Cancer Market Overview

• Epithelial Ovarian Cancer market size has reached to $2.41 billion in 2025 • Expected to grow to $5.03 billion in 2030 at a compound annual growth rate (CAGR) of 15.7% • Growth Driver: Rising Ovarian Cancer Prevalence To Drive Growth In The Market • Market Trend: Innovative Targeted Therapies Transforming Cancer Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Epithelial Ovarian Cancer Market?

Epithelial ovarian cancer is the most common type of ovarian cancer, originating from the epithelial cells that form the outer layer of the ovary. Most often, it affects women over fifty. EOC is often asymptomatic in its early stages, leading to late diagnoses when the disease has already progressed. Symptoms, when present, may include abdominal bloating, pelvic pain, frequent urination, and changes in bowel habits. The main types of treatments for epithelial ovarian cancer include chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and surgery. Chemotherapy refers to a cancer treatment using drugs to destroy cancer cells or slow their growth. It offers various drugs such as platinum-based chemotherapy drugs, poly(adp-ribose) polymerase inhibitors, bevacizumab, and chemotherapeutic agents, and is used for early and advanced stages of cancer. It can be diagnosed using various methods such as imaging, biopsy, and blood tests, and is used by hospitals, clinics, and diagnostic laboratories.

What Is The Epithelial Ovarian Cancer Market Growth Forecast?

The epithelial ovarian cancer market size is expected to see rapid growth in the next few years. It will grow to $5.03 billion in 2030 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to precision oncology adoption, biomarker-based diagnostics, immunotherapy pipeline growth, early screening awareness, improved survival outcomes. Major trends in the forecast period include rising adoption of targeted therapies, increased use of combination treatment regimens, growth in early diagnostic technologies, expansion of immunotherapy applications, emphasis on personalized oncology care.

Global Epithelial Ovarian Cancer Market Segmentation

1) By Type Of Treatment: Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Surgery 2) By Drug Class: Platinum-Based Chemotherapy Drugs, Poly (ADP-ribose) Polymerase Inhibitors, Bevacizumab, Chemotherapeutic Agents 3) By Stage Of Cancer: Early Stage, Advanced Stage 4) By Diagnosis Method: Imaging, Biopsy, Blood Tests 5) By End User: Hospitals, Clinics, Diagnostic Laboratories Subsegments: 1) By Chemotherapy: Platinum-Based Chemotherapy, Non-Platinum Chemotherapy, Combination Chemotherapy 2) By Targeted Therapy: Monoclonal Antibodies, PARP Inhibitors, Angiogenesis Inhibitors 3) By Immunotherapy: Checkpoint Inhibitors, Cancer Vaccines, Adoptive T-Cell Therapy 4) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Progestins 5) By Surgery: Debulking Surgery, Oophorectomy, Hysterectomy

What Is The Driver Of The Epithelial Ovarian Cancer Market?

The increasing prevalence of ovarian cancer is expected to propel the growth of the epithelial ovarian cancer market going forward. Ovarian cancer is a cancer that starts in the ovaries, primarily affecting the epithelial cells that cover the surface of the ovaries. The increasing prevalence of ovarian cancer is primarily due to an aging population, improved awareness, and higher detection rates, along with genetic and lifestyle factors. Epithelial ovarian cancer treatment is required to address the most common and aggressive form of ovarian cancer, targeting malignant cells to improve survival rates and patient outcomes. For instance, in February 2024, according to the World Ovarian Cancer Coalition, a Canada-based non-profit organization, by 2050, the global number of women diagnosed with ovarian cancer is expected to increase by over 55%, reaching 503,448. Annual deaths from ovarian cancer are projected to rise to 350,956, reflecting a nearly 70% increase from 2022. Therefore, the increasing prevalence of ovarian cancer will drive the epithelial ovarian cancer industry going forward.

Key Players In The Global Epithelial Ovarian Cancer Market

Major companies operating in the epithelial ovarian cancer market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck KGaA, Siemens Healthineers AG, Quest Diagnostics Incorporated, Eisai Co. Ltd., Genentech Inc., Qiagen N.V., Myriad Genetics Inc., Clovis Oncology Inc., Fujirebio Diagnostics Inc.

Global Epithelial Ovarian Cancer Market Trends and Insights

Major companies operating in the epithelial ovarian cancer market are focusing on developing innovative treatment options, such as FRα-directed antibody-drug conjugates (ADCs), to specifically target folate receptor-alpha overexpressed on cancer cells, delivering potent cytotoxic agents while minimizing harm to healthy tissues. An FRα-directed antibody-drug conjugate (ADC) is a targeted cancer therapy that links an antibody specific to the folate receptor-alpha (FRα) to a cytotoxic drug, delivering the drug directly to cancer cells expressing this receptor. For instance, in November 2024, AbbVie Inc., a US-based biopharmaceutical company, received European Commission approval for ELAHERE (mirvetuximab soravtansine), a targeted treatment for adult patients with folate receptor-alpha (FRα) positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. ELAHERE provides a new, effective treatment option for patients who have received up to three prior systemic regimens. It targets a biomarker found in about one-third of ovarian cancer patients, enhancing the chance of survival and improving quality of life. The approval includes a companion diagnostic to identify suitable patients.

What Are Latest Mergers And Acquisitions In The Epithelial Ovarian Cancer Market?

In February 2024, AbbVie Inc., a US-based biopharmaceutical company, acquired ImmunoGen for a deal of $10.1 billion. The acquisition aims to enhance its oncology portfolio by adding ELAHERE, a targeted antibody-drug conjugate for treating platinum-resistant ovarian cancer, thereby reducing reliance on its older drugs and positioning itself in the growing ADC market. ImmunoGen is a US-based manufacturer of drugs for epithelial ovarian cancer.

Regional Outlook

North America was the largest region in the epithelial ovarian cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Epithelial Ovarian Cancer Market?

The epithelial ovarian cancer market consists of revenues earned by entities by providing services such as genetic testing, supportive care services, telemedicine, and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The epithelial ovarian cancer market also includes sales of diagnostic kits, targeted therapy drugs, chemotherapeutic agents, surgical instruments, and devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Epithelial Ovarian Cancer Market Report 2026?

The epithelial ovarian cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the epithelial ovarian cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.